NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)
The CASSIOPEIA trial IFM / HOVON IFM 2015-01 HOVON HO131 MM Newly Diagnosed Multiple Myeloma A Study to Evaluate Daratumumab in...
Dec 31, 2015
719
NCT02336815 : Phase 2 - Selinexor Treatment of Refractory Myeloma (STORM)
STORM Selinexor Treatment of Refractory Myeloma (STORM) This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg...
Dec 30, 2015
229
NCT02332850: Phase Ib Study of SAR650984 With Carfilzomib for Treatment of Relapsed Multiple Myeloma
Multiple Myeloma Research Consortium NCT02332850: Phase Ib Study of SAR650984 With Carfilzomib for Treatment of Relapsed Multiple Myeloma...
Dec 23, 2015
176
Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Targeted Therapy)
Cleveland Clinic Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Targeted Therapy)
Dec 20, 2015
21
Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Chemotherapy)
Cleveland Clinic: Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Chemotherapy)
Dec 20, 2015
137
Myeloma UK - Myeloma Animations Series: Proteasome inhibitors in myeloma
Myeloma UK - Myeloma Animations Proteasome inhibitors in myeloma Learn More: https://www.myeloma.org.uk/
Dec 19, 2015
92
NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma
NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma This is a Phase 2 study to assess the good and bad effects of...
Dec 19, 2015
118
Myeloma UK - Myeloma Animations Series: Immunotherapy in myeloma
Myeloma UK - Myeloma Animations Immunotherapy in myeloma Learn More: https://www.myeloma.org.uk/
Dec 19, 2015
116
NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial
GEM-CESAR trial PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en...
Dec 19, 2015
472
FDA Approved for RRMM: Elotuzumab (Empliciti) with lenalidomide and dexamethasone (Rd)
11/30/2015: Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple...
Dec 19, 2015
34
NCT02612779: Phase 2 - Elotuzumab in Combination With Pomalidomide and Low dose Dex Vs Nivo/Elo
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab...
Dec 18, 2015
182
NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)
STOMP Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP) This study will independently assess the efficacy and safety...
Dec 18, 2015
453
FDA Approved for RRMM: Panobinostat (Farydak) Capsules + Bortezomib (Velcade) and Dexamethasone
FDA Approved for RRMM: Panobinostat (Farydak) Capsules + Bortezomib(Velcade) and Dexamethasone Relapsed & Refractory Multiple Myeloma...
Dec 17, 2015
90
Myeloma UK - Myeloma Animations Series: Genetic causes of myeloma
Myeloma UK - Myeloma Animations Genetic causes of myeloma Learn More: https://www.myeloma.org.uk/
Dec 17, 2015
47
Nature Videos: Tumour immunology and immunotherapy
Nature Videos: Tumour immunology and immunotherapy https://www.nature.com/
Dec 15, 2015
104
FDA Approved for RRMM: Kyprolis (carfilzomib) + Revlimid (lenalidomide) and Dexamethasone (KRd)
July 24, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved the...
Dec 14, 2015
139
NCT02495922: Phase 3 - Elotuzumab in VRD Induction /Consolidation and Len maint in NDMM(GMMG-HD6)
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly...
Dec 13, 2015
231
FDA Approved for RRMM: Daratumumab (Darzalex)
HORSHAM, PA, November 16, 2015 – Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today the U.S....
Dec 12, 2015
66
FDA Approved for NDMM: Lenalidomide (Revlimid)
SUMMIT, N.J., February 18, 2015 --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug...
Dec 12, 2015
33